Oct 10, 2018
TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant
Sep 26, 2018
Advances in Breast and Gastric Cancer Research Presented for the First Time at the 2018 World Molecular Imaging Congress
Sep 24, 2018
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer
Sep 13, 2018
HERCEPTIN® (trastuzumab) subcutaneous (SC) formulation approved in Canada for the treatment of HER2-positive breast cancer
Sep 06, 2018
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
Sep 04, 2018
Health Canada approves PERJETA® (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery
Aug 09, 2018
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Trastuzumab Biosimilar to Treat Breast Cancer
Jun 28, 2018
CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial
Jun 18, 2018
Published Case Report Demonstrates the Clinical Utility of Biocept's CTC Platform in the Management of Patients with Metastatic Breast Cancer
Jun 18, 2018
Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies
Jun 04, 2018
MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 03, 2018
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Jun 01, 2018
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri(TM), the first biosimilar for Herceptin® approved by FDA
Jun 01, 2018
Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with HER3-Expressing Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
May 30, 2018
Updated Guideline for HER2 Testing in Breast Cancer Aids Physicians, Patients and their Families
May 23, 2018
Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications
May 16, 2018
Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 05, 2018
TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update
Apr 05, 2018
Specialised Therapeutics Asia Initiates Early Access Program For Neratinib